Drug Trial Radar · NCT07341737
SL-28 for Advanced Solid Tumours
Last checked: Nov 19, 2026Latest source record: Sep 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Aug 14, 2026
Primary completion
Jan 1, 2027
Study completion Mar 1, 2027
Sponsor
- Lead sponsor
- Second Life TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Jan 14, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Second Life Therapeutics is developing SL-28, an allogeneic, non-genetically modified cell-based therapy for the treatment of advanced solid tumours. The company has recently demonstrated a novel, non-genetic approach to modulate immune cell activity through targeted manipulation of the Universal Receptive System. The purpose of this open label, multi-center clinical trial is to evaluate the anti-tumor activity, safety, and pharmacokinetics, single-agent SL-28 in patients with a diverse array of solid tumors. The study includes an initial Phase 1 dose escalation to determine recommended dose(s) for expansion of SL-28 as a monotherapy and Phase 2 expansion cohorts. The study will enroll patients with advanced solid tumours, including those who failed previous lines of chemo- and immunotherapies.
Conditions
- Head & Neck Cancer
- Pancreas Carcinoma
- Pancreas Cancer, Metastatic
- Lung Adenocarcinoma
- Lung Cancer (NSCLC)
- Lung Cancer (Non-Small Cell)
- Esophageal Cancer
- Stomach (Gastric) Cancer
- Liver Cancer
- Intestinal Cancer
- Bladder Cancer
- Renal Cancer
- Prostate Cancer
- Melanoma (Skin Cancer)
- Breast Cancer
- Ovarian Cancer
- Endometrial Cancer
- Colorectal Cancer
Interventions
SL-28Biological
Doses administered: 3×10\^7 cells/injection, once daily, 5 days per week, 12 weeks. Mode of administration: intravenous push
SL-28Biological
Doses administered: 6×10\^7 cells/injection, once daily, 5 days per week, 12 weeks. Mode of administration: intravenous push
SL-28Biological
Doses administered: to-be-determeined-later Mode of administration: intravenous push
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with treatment-emergent adverse eventsTime frame: 12 weeks
- To evaluate the safety and tolerability of SL-28 by determining the incidence of dose-limiting toxicitieswithin the first 28 days after infusion.Time frame: 12 weeks
- Change from baseline in ECG QT intervalTime frame: 12 weeks
- Change from baseline in vital signsTime frame: 12 weeks
- Change from baseline in vital signsTime frame: 12 weeks
- Change from baseline in vital signsTime frame: 12 weeks
- Number of participants with dose-limiting toxicities (DLTs)Time frame: 12 weeks
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Liverpool Hospital
Sydney, New South Wales, Australia · Not yet recruiting
John Flynn Private Hospital
Gold Coast, Queensland, Australia · Not yet recruiting
The Southern Oncology Clinical Research Unit (SOCRU)
Adelaide, South Australia, Australia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.